dc.contributor.author | Yarnold, JR | |
dc.contributor.author | Brunt, AM | |
dc.contributor.author | Chatterjee, S | |
dc.contributor.author | Somaiah, N | |
dc.contributor.author | Kirby, AM | |
dc.date.accessioned | 2022-05-10T11:56:48Z | |
dc.date.accessioned | 2022-05-10T11:58:39Z | |
dc.date.available | 2022-05-10T11:58:39Z | |
dc.date.issued | 2022-05-01 | |
dc.identifier.citation | Clinical oncology (Royal College of Radiologists (Great Britain)), 2022, 34 (5), pp. 332 - 339 | |
dc.identifier.issn | 0936-6555 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5122 | |
dc.identifier.eissn | 1433-2981 | |
dc.identifier.eissn | 1433-2981 | |
dc.identifier.doi | 10.1016/j.clon.2022.03.001 | |
dc.identifier.doi | 10.1016/j.clon.2022.03.001 | |
dc.description.abstract | There is a sound empirical basis for hypofractionation in radiotherapy for breast cancer. This article reviews the radiobiological implications of hypofractionation in breast cancer derived from a series of clinical trials that began when 50 Gy in 25 fractions over 5 weeks was commonplace. These trials led first to 40 Gy in 15 fractions over 3 weeks and, subsequently, to 26 Gy in five fractions over 1 week being adopted as standards of care for many patients prescribed whole- or partial-breast radiotherapy after primary surgery. | |
dc.format | Print-Electronic | |
dc.format.extent | 332 - 339 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | ELSEVIER SCIENCE LONDON | |
dc.relation.replaces | https://repository.icr.ac.uk/handle/internal/5121 | |
dc.relation.replaces | internal/5121 | |
dc.rights.uri | http://www.rioxx.net/licenses/all-rights-reserved | |
dc.subject | Breast | |
dc.subject | Humans | |
dc.subject | Breast Neoplasms | |
dc.subject | Treatment Outcome | |
dc.subject | Radiotherapy, Adjuvant | |
dc.subject | Female | |
dc.subject | Radiation Dose Hypofractionation | |
dc.title | From 25 Fractions to Five: How Hypofractionation has Revolutionised Adjuvant Breast Radiotherapy. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2022-03-01 | |
rioxxterms.version | AM | |
rioxxterms.versionofrecord | 10.1016/j.clon.2022.03.001 | |
dc.relation.isPartOf | Clinical oncology (Royal College of Radiologists (Great Britain)) | |
pubs.issue | 5 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Breast Cancer Radiotherapy | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Breast Cancer Radiotherapy/Breast Cancer Radiotherapy (hon.) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Translational Breast Radiobiology | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Accepted | |
pubs.volume | 34 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Breast Cancer Radiotherapy | |
icr.researchteam | Translational Breast Radiobiology | |
dc.contributor.icrauthor | Yarnold, John | |
dc.contributor.icrauthor | Somaiah, Navita | |